Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3)

Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3)

IntroductionColorectal cancer (CRC) is the third most common cancer worldwide in men and women. In the metastasized stage, treatment options and prognosis are limited. To address the high medical need of this patient population, we generated a CD276xCD3 bispecific antibody termed CC-3. CD276 is expr...

Full description

Bibliographic Details
Main Authors: Susanne Jung, Richard F. Schlenk, Christopher Hackenbruch, Sandra S.L. Roldan Pinzon, Michael Bitzer, Martin Pflügler, Juliane S. Walz, Gundram Jung, Jonas S. Heitmann, Helmut R. Salih
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-02-01
Series:Frontiers in Oncology
Subjects:
colorectal cancer
bispecific antibody
CD276
immunotherapy
clinical trial
translational immunology
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1351901/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1351901/full

Similar Items